Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | RPA1 | P27694 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105667 | 1.00 | MGLL (0.54) | MGLLPTGS2ALOX5RPA1PTGS1 | |
| SCHEMBL3100407 | 0.96 | PTGS2 (0.50) | MGLLPTGS2ALOX5RPA1PTGS1 | |
| SCHEMBL3103064 | 0.93 | MGLL (0.46) | MGLLPTGS2RPA1MALT1 | |
| SCHEMBL3104741 | 0.92 | CCKAR (0.47) | PTGS2ALOX5 | |
| SCHEMBL13157636 | 0.91 | PTGS2 (0.58) | PTGS2ALOX5PTGS1MALT1 | |
| SCHEMBL13157631 | 0.91 | PTGS2 (0.48) | MGLLPTGS2ALOX5RPA1PTGS1 | |
| SCHEMBL13157600 | 0.91 | PTGS2 (0.58) | PTGS2ALOX5PTGS1MALT1 | |
| SCHEMBL3098701 | 0.91 | KCNJ6 (0.51) | MGLLPTGS2ALOX5RPA1KCNJ6 | |
| SCHEMBL13157624 | 0.91 | BCL2 (0.47) | MGLLPTGS2ALOX5RPA1PTGS1 | |
| SCHEMBL13157611 | 0.91 | ALOX5 (0.48) | MGLLPTGS2ALOX5PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2009006-A1 | UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | MGLL 1894/4885PTGS2 567/4885ALOX5 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.